Kubvumidzwa kweMinjuvi® (Tafasitamab) pamwe chete neLenalidomide pakurapa Varwere Vakuru vane Relapsed kana Refractory Diffuse Large B-Cell Lymphoma muChina

Musi wa21 Chivabvu, 2025, InnoCare Pharma yakazivisa kuti China National Medical Products Administration (NMPA) yabvumidza Minjuvi® (tafasitamab), mushonga weFc-modified cytolytic CD19 unorwisa monoclonal antibody, pamwe chete nelenalidomide, uchiteverwa neMinjuvi monotherapy, yekurapa varwere vakuru vane relapse or refractory diffuse large B-cell lymphoma (DLBCL) vasingakodzeri kuisirwa autologous stem cell transplant (ASCT). Uyu ndiwo mushonga wekutanga weCD19 wakatenderwa kurapa relapse or refractory DLBCL muChina.

d8c9d779f0a78de8217298eaa38c05a.png

NezveTafasitamab

Tafasitamab iFc-modified cytolytic CD19 inogadziriswa nemunhu inotarisa monoclonal antibody. Tafasitamab inosanganisira Fc domain yakagadzirwa, iyo inodzora B-cell lysis kuburikidza neapoptosis uye immune effector mechanism inosanganisira Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) uye Antibody-Dependent Cellular Phagocytosis (ADCP).

MorphoSys naIncyte vakapinda muchibvumirano che: (a) muna Ndira 2020, chibvumirano chekushandira pamwe chete uye chekupa marezenisi ekugadzira nekutengesa tafasitamab pasi rose; uye (b) muna Kukadzi 2024, chibvumirano apo Incyte yakawana kodzero dzakasarudzika dzekugadzira nekutengesa tafasitamab pasi rose.

Muna Nyamavhuvhu 2021, Incyte yakapinda muchibvumirano chekushandira pamwe nerezenisi neInnoCare chekuvandudza nekutengesa tafasitamab muropa nekenza muGreater China.

MuUnited States, Monjuvi (tafasitamab-cxix) yakagamuchira mvumo yekukurumidza kubva kuUS Food and Drug Administration pamwe chete nelenalidomide yekurapa varwere vakuru vane DLBCL yakadzoka kana kuti isingarapike isina kutaurwa neimwe nzira, kusanganisira DLBCL inobva ku low grade lymphoma, uye vasingakodzeri kuisirwa autologous stem cell transplant (ASCT). MuEurope, Minjuvi (tafasitamab) yakagamuchira mvumo yekushambadzira ine chekuita neEuropean Medicines Agency pamwe chete nelenalidomide, ichiteverwa neMinjuvi monotherapy, yekurapa varwere vakuru vane relapse or refractory diffuse large B-cell lymphoma (DLBCL) vasingakodzeri kuisirwa autologous stem cell transplant (ASCT).

Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.

Nhamba yefoni: 4008803716

Email:myimmnet@163.com

微信图片_20241115181717


Nguva yekutumira: Chivabvu-27-2025